BSE Live
Mar 24, 11:54Prev. Close
369.00
Open Price
375.00
Bid Price (Qty.)
388.30 (16)
Offer Price (Qty.)
389.70 (453)
NSE Live
Mar 24, 11:54Prev. Close
368.75
Open Price
376.65
Bid Price (Qty.)
388.70 (3)
Offer Price (Qty.)
389.10 (24)
| Cash Flow of SMS Pharmaceuticals (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 50.76 | 62.35 | 60.35 | 41.58 | 56.27 | |
| Net CashFlow From Operating Activities | 39.71 | 49.76 | 31.81 | 73.47 | 61.22 | |
| Net Cash Used In Investing Activities | -42.56 | -34.67 | -16.58 | -38.96 | -96.72 | |
| Net Cash Used From Financing Activities | -2.40 | -12.92 | -14.89 | -33.19 | 26.65 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -5.25 | 2.17 | 0.35 | 1.32 | -8.84 | |
| Cash And Cash Equivalents Begin of Year | 14.80 | 12.63 | 12.29 | 10.96 | 20.09 | |
| Cash And Cash Equivalents End Of Year | 9.54 | 14.80 | 12.63 | 12.29 | 11.25 |
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
09.02.2026
05.01.2026
18.02.2026
SMS Pharma Consolidated December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
10.02.2026
SMS Pharma Standalone December 2025 Net Sales at Rs 210.45 crore, up 21.4% Y-o-Y
14.11.2025
SMS Pharma Consolidated September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
12.11.2025
SMS Pharma Standalone September 2025 Net Sales at Rs 242.43 crore, up 23.22% Y-o-Y
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth